Andy is a seasoned pharmaceutical marketing executive with three decades of commercial experience spanning business strategy, global launches, and client leadership across major pharmaceutical companies. He joins Shearwater Global as Senior Advisor to help grow the firm’s healthcare capability across pharmaceuticals, medical devices, health and wellness.

Andy began his career in 1995 at MSD, gaining sales and marketing experience before transitioning to marketing services in 2001. He joined Paling Walters with Pfizer as his first assignment, achieving rapid promotion through various roles including pioneering a digital patient segmentation programme for a major migraine brand launch.

In 2009, Paling Walters was acquired by TBWA\Group, where Andy developed launch excellence expertise through global launches across multiple therapy areas.

He successfully launched over 20 brands in 10 years for pharmaceutical companies including AstraZeneca, Pfizer, GSK, Novartis, and Roche. In 2010 he was appointed Omnicom’s global Pfizer lead, delivering commercial advantage for them by integrating marketing services companies around unified brand strategies.

In 2013, Andy co-founded Loooped LLP, a strategic creative consultancy supporting marketing teams with positioning and brand revitalisation challenges. The firm operated as strategic architects, developing marketing blueprints for pharmaceutical clients before being sold back to equity partners in 2018.

Andy returned to Omnicom in 2018 to modernise TBWA\WorldHealth into an omnichannel, customer experience-focused business for pharmaceutical companies including AstraZeneca, Pfizer, Novartis, Takeda, Merck, Teva, Sobi, and Moderna. He was appointed Managing Partner of TBWA\WorldHealth London in 2018, then Global Managing Partner in 2020, creating channel-agnostic, integrated plans for clients across verticals.

From 2022 to 2025, Andy led the post-merger integration of two legacy healthcare agencies, transforming operations and culture through capability shifts to data-driven strategy models and customer content-centric creative approaches, preparing the agency for renewed year-on-year growth.

His leadership culminated in his most recent assignment as global and US brand lead for AstraZeneca’s PARP-inhibitor Lynparza, maintaining the brand’s global market leadership through strategic planning, indication launches, and integration of diagnostic and therapeutic programmes. Andy also maintains an independent consultancy practice providing senior advisory services across the healthcare industry, with deep expertise in oncology, diabetes, cardiovascular, neurology, women’s health, and consumer health.